| Identification | Back Directory | [Name]
Benzeneaceticacid,3,5-dihydroxy-2-(1-oxononyl)-,pentylester | [CAS]
1257228-26-4 | [Synonyms]
Amoitone-B
(3,5-Dihydroxy-2-nonanoyl-phenyl)-acetic acid pentyl ester
Benzeneaceticacid,3,5-dihydroxy-2-(1-oxononyl)-,pentylester | [Molecular Formula]
C22H34O5 | [MDL Number]
MFCD18632550 | [MOL File]
1257228-26-4.mol | [Molecular Weight]
378.5 |
| Chemical Properties | Back Directory | [Boiling point ]
517.3±29.0 °C(Predicted) | [density ]
1.074±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: >65mg/mL | [form ]
powder | [pka]
7.51±0.40(Predicted) | [color ]
white |
| Hazard Information | Back Directory | [Uses]
Amoitone B, a derivative of cystosporone B, is an agonist of NR4A1. Amoitone B has anticancer activity[1]. | [Biological Activity]
n-Amyl 2-[3,5-dihydroxy-2-(1-nonanoyl)phenyl]acetate is a Nur77 agonist. Nur77 is a steroid orphan receptor th at plays a critical role in regulating proliferation, differentiation and apoptosis. n-Amyl 2-[3,5-dihydroxy-2-(1-nonanoyl)phenyl]acetate, a cytosporone B analog, is a stronger activator of Nur77 than it parent compound. n-Amyl 2-[3,5-dihydroxy-2-(1-nonanoyl)phenyl]acetate treatment causes Nur77 migration to mitochondria, which results in mitochondrial Cyt c release into the cytoplasm and mitochondrial AIF redistribution in both the cytoplasm and nucleus. | [References]
[1] Zhang L, et al. The Orphan Nuclear Receptor 4A1: A Potential New Therapeutic Target for Metabolic Diseases. J Diabetes Res. 2018 Jun 14;2018:9363461. DOI:10.1155/2018/9363461 |
|
| Company Name: |
Wuxi AppTec
|
| Tel: |
022-59987777 13552403979 |
| Website: |
www.labnetwork.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|